CD4+ Count, Among Other Factors, Heightened Risk For Severe Mpox Infection
March 2, 2026
New research presented at IDWeek underscores that the intersection of HIV and mpox risk is shaped as much by access to care as by immunology. Data from New York City suggest that low CD4+ counts, untreated HIV, and coexisting infections such as syphilis were stronger predictors of severe mpox than viral load alone. Qualitative findings further reveal that stigma, provider uncertainty, and fear delayed care. Mpox severity among people with HIV reflects structural vulnerabilities that demand both clinical vigilance and equitable access to sustained HIV care.
The relationship between HIV and mpox severity is more complex than a single laboratory value. Research presented at IDWeek offers critical insight into how immunologic status, health care engagement, and structural inequities intersected during the 2022 outbreak in New York City.
In one study of men with HIV who received tecovirimat as a proxy for severe mpox, hospitalization was not independently associated with lack of viral suppression after adjustment. Instead, low CD4+ counts, absence of antiretroviral therapy, and concurrent syphilis infection were more strongly linked to severe outcomes. As investigators at NYC Health + Hospitals/Bellevue observed, these markers likely reflect inconsistent access to comprehensive HIV care rather than isolated biologic vulnerability. CD4+ count alone does not define risk. It signals broader gaps in engagement with the health system.
The data also revealed disproportionate hospitalization among Black men, reinforcing patterns seen across infectious disease outbreaks. Structural racism, insurance barriers, and differential access to prevention and treatment amplify vulnerability long before viral exposure occurs. As infectious disease specialist Bruce Aldred of Emory University School of Medicine noted, marginalized communities are often the last to receive timely education and resources.
A companion qualitative study further exposed the human dimension of these disparities. Many patients described encountering fear or uncertainty from clinicians unfamiliar with mpox management. Delayed care, inadequate pain control, and stigma compounded the burden of isolation. Yet participants also identified examples of compassionate, respectful care that fostered trust and recovery.
Together, these findings suggest that reducing severe mpox outcomes among people with HIV requires more than antiviral availability. It demands sustained investment in HIV care continuity, stigma reduction, provider education, and culturally competent clinical practice. Mpox severity is not merely a virologic phenomenon. It reflects the health system’s capacity to engage and protect those most at risk.